Indication
Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Loading your page…
Loading your page…
Asthma
Marketing Authorisation Holder: Teva B.V.
EMA Authorisation: 15/08/2016
INN: reslizumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Cinqaero: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.